FDA Brief

Warning letters Drugs

FDA warning letter to

UPSY LLC

High riskIssued Mar 28, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned UPSY LLC that its website sells CBD products claimed to treat or prevent COVID-19 as unapproved, misbranded drugs.

What happened

FDA reviewed the company's website, www.upsy.com, on February 17, 2022, and the FTC reviewed it on March 15, 2022. The site offered cannabidiol (CBD) products for sale with blog posts saying CBD "may help patients cope with symptoms" of COVID-19, is "a potent anti-inflammatory" in the fight against COVID, and "can mitigate ARDS-like symptoms." No inspection was conducted; the findings come from the website review.

What FDA found

  1. The company sells CBD products as treatments for COVID-19 without FDA approval, which makes them unapproved new drugs.

    Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded because their labeling makes claims the drug has not been approved for.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Shipping these products across state lines is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertises that its products prevent, treat or cure disease without competent and reliable scientific evidence, which the FTC Act forbids.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. Deceptive claims about treating, curing, preventing or mitigating COVID-19 can bring civil penalties of up to $46,517 per violation.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
  6. The company must stop making unsubstantiated COVID-19 claims and may have to refund consumers.

    Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b)

What FDA wants

FDA tells the company to immediately stop selling unapproved products claimed to prevent or treat COVID-19, and within 48 hours to email COVID-19-Task-Force-CDER@fda.hhs.gov describing the steps taken and how it will prevent repeat violations. The FTC separately requires a certification within 48 hours that the unsubstantiated claims have stopped.

Who should pay attention

  • CBD and supplement brands that make health claims on their websites
  • e-commerce sellers of CBD and wellness products
  • marketing and regulatory reviewers who approve online product content

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk